© Reuters. FILE PHOTO: General view shows the laboratories of BioNTech at their COVID-19 vaccine production facility as the spread of the coronavirus disease (COVID-19) continues, in Marburg, Germany, March 27, 2021. REUTERS/Kai Pfaffenbach/File Photo
FRANKFURT (Reuters) – Pharma-Park Marburg, where German drugmaker BioNTech produces its COVID-19 vaccine, has been put up for sale in a potential 450 million euro ($531 million) deal, three people close to the matter said.
The biotech-focused industrial park, which also counts GSK, Healthineers and CSL (OTC:) Behring as tenants, has been offered for sale by its owner Infrareal, they said.
Insurer Swiss Life and infrastructure investor Ancala are expected to submit binding bids in coming days, the people added.
Infrareal and Ancala were not immediately available for comment, while Swiss Life declined to comment.
Pharma-Park Marburg has annual earnings before interest, tax, depreciation and amortisation of about 25 million euros and could be valued at 400-450 million euros, the people said.
The industrial park covers an area of 67.4 hectares, and approximately 6,000 employees work there.
($1 = 0.8481 euros)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment